Future of InterMune's Esbriet in doubt as US FDA issues complete response letter
This article was originally published in Scrip
The US FDA has hit InterMune's idiopathic pulmonary fibrosis (IPF) drug candidate Esbriet (pirfenidone) with a complete response letter refusing to approve the drug until the company conducts another clinical trial to support efficacy.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.